

Reimbursement Policy

Diabetes Mellitus Testing

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Diabetes describes several heterogeneous diseases in which various genetic and environmental factors can result in the progressive loss of β -cell mass and/or function that manifests clinically as hyperglycemia.¹ Fasting plasma glucose (FPG) and oral glucose tolerance testing (OGTT) can be used in the diagnosis of diabetes mellitus. FPG is obtained from blood after a typically overnight period of not eating, whereas the OGTT is performed to understand an individual's response to a concentrated solution of glucose after two hours, typically in the setting of pregnancy.² In an asymptomatic individual, $\text{FPG} \geq 126 \text{ mg/dL}$ or two-hour plasma glucose values of $\geq 200 \text{ mg/dL}$ during a 75 g OGTT establish a diagnosis of diabetes. In reference to A1c values, individuals with percentages 5.7 to $<6.5\%$ are at highest risk. Additionally, there is a continuum of increasing risk amongst individuals with A1c levels $<6.5\%$.³ These assays are identified to be affordable alternatives to the more costly yet more convenient HbA1c level, and are more often used in the diagnosis of type 2 diabetes mellitus.⁴

Glycated hemoglobin (A1c) results from post-translational attachment of glucose to the hemoglobin in red blood cells at a rate dependent upon the prevailing blood glucose concentration. Therefore, these levels correlate well with glycemic control over the previous eight to twelve weeks.⁵ The measurement of hemoglobin A1c is recommended for diabetes management, including screening, diagnosis, and monitoring for diabetes and prediabetes.

Terms such as male and female are used when necessary to refer to sex assigned at birth.

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) For individuals with acute or persistent classic symptoms of diabetes mellitus, measurement of plasma glucose **MEETS COVERAGE CRITERIA**.

Reimbursement Policy

- 2) For individuals with a diagnosis of either type 1 or type 2 diabetes mellitus, measurement of hemoglobin A1c **MEETS COVERAGE CRITERIA** in **any** of the following situations:
 - a) Upon initial diagnosis to establish a baseline value and to determine treatment goals.
 - b) Twice a year (every 6 months) in individuals who are meeting treatment goals and who, based on daily glucose monitoring, appear to have stable glycemic control.
 - c) Quarterly in individuals who are not meeting treatment goals for glycemic control.
 - d) Quarterly in individuals whose pharmacologic therapy has changed.
 - e) Quarterly for individuals who are pregnant.
- 3) For prediabetic individuals, annual screening for type 2 diabetes with a fasting plasma glucose test **or** measurement of hemoglobin A1c **MEETS COVERAGE CRITERIA**.
- 4) For asymptomatic individuals who are 35 years of age or older and who have no risk factors for diabetes, screening for prediabetes or type 2 diabetes once every three years with a fasting plasma glucose test **MEETS COVERAGE CRITERIA**.
- 5) For individuals 18 years of age or older, screening once every three years for prediabetes or type 2 diabetes with a fasting plasma glucose test or measurement of hemoglobin A1c **MEETS COVERAGE CRITERIA** for individuals with **any** of the following risk factors:
 - a) For individuals who are overweight or obese.
 - b) For first-degree relatives (see Note 1) of individuals with diabetes.
 - c) For individuals with a history of cardiovascular disease.
 - d) For individuals with hypertension.
 - e) For individuals with hypercholesterolemia.
 - f) For individuals with metabolic syndrome.
 - g) For individuals who are obese and have acanthosis nigricans.
 - h) For individuals with polycystic ovary syndrome.
 - i) For individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
 - j) For individuals who were previously diagnosed with gestational diabetes mellitus (GDM).
- 6) For individuals who are positive for HIV, screening for diabetes and prediabetes with a fasting plasma glucose test **MEETS COVERAGE CRITERIA** in **any** of the following situations:
 - a) For individuals starting antiretroviral therapy (ART).
 - b) For individuals switching their ART.

Reimbursement Policy

- c) 3-6 months after starting or switching antiretroviral therapy.
 - d) Annually when screening results were initially normal.
- 7) For individuals 10 years of age and older who have been diagnosed with cystic fibrosis (CF) but not with CF-related diabetes, annual screening for CF-related diabetes with an OGTT **MEETS COVERAGE CRITERIA**.
- 8) For overweight or obese individuals less than 18 years of age, diabetes screening once every three years with a fasting plasma glucose test, an OGTT, **or** measurement of hemoglobin A1c **MEETS COVERAGE CRITERIA** for individuals with **any** of the following risk factors:
- a) The individual has a maternal history of diabetes or gestational diabetes mellitus during the child's gestation.
 - b) The individual has a family history of type 2 diabetes in first- or second-degree relatives (see Note 1).
 - c) The individual has signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight).
- 9) For pregnant individuals, a fasting plasma glucose test or an OGTT up to once per month during pregnancy **MEETS COVERAGE CRITERIA**.
- 10) For individuals diagnosed with GDM during pregnancy, an OGTT **MEETS COVERAGE CRITERIA** in **any** of the following situations:
- a) To screen for persistent diabetes or prediabetes 4-12 weeks postpartum.
 - b) For individuals with a positive initial postpartum screening result, repeat screening to confirm a diagnosis of persistent diabetes or prediabetes.
- 11) For all other situations not addressed above, fasting plasma glucose testing at a wellness visit with no abnormal findings **DOES NOT MEET COVERAGE CRITERIA**.
- 12) For all other situations not previously described (see Note 2), measurement of hemoglobin A1c **DOES NOT MEET COVERAGE CRITERIA**.

NOTES:

Note 1: First-degree relatives include parents, full siblings, and children of the individual. Second-degree relatives include grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings of the individual.

Reimbursement Policy

Note 2: Measurement of hemoglobin A1c **should not** be performed in **any** of the following situations:

- 1) To test for diabetes in individuals presenting with acute or persistent classic symptoms of diabetes mellitus.
- 2) In pregnant individuals without an established diagnosis of diabetes or prediabetes.
- 3) To screen for diabetes in individuals diagnosed with cystic fibrosis.
- 4) In conjunction with measurement of fructosamine.
- 5) In individuals with a condition associated with increased red blood cell turnover (e.g., individuals with sickle cell disease or who are HIV positive, individuals receiving hemodialysis or erythropoietin therapy or who have had recent blood loss or a transfusion).

Note 3: Allow A1C testing once every calendar year for individuals without a diagnosis of Diabetes for CPT codes 83036 and 83037. Otherwise, there is no limit for individuals with diagnosis of Diabetes.

- 1) CPT 83036 → Lab-based, delayed results.
- 2) CPT 83037 → Point-of-care, immediate results.
- 3) Both are valid CPT billing codes and must be used correctly depending on where and how the test is performed. Misuse (e.g., billing 83037 when the test was sent to a lab) can lead to claim denials.

III. **Applicable State and Federal Regulations**

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Reimbursement Policy

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
82947	Glucose; quantitative, blood (except reagent strip)
82951	Glucose; tolerance test (GTT), 3 specimens (includes glucose)
82952	Glucose; tolerance test, each additional beyond 3 specimens
82985	Glycated protein
83036	Hemoglobin; glycosylated (A1C)
83037	Hemoglobin; glycosylated (A1C) by device cleared by FDA for home use

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. *Diabetes*. Feb 2017;66(2):241-255. doi:10.2337/db16-0806
2. MayoClinic. Glucose Tolerance Test. Updated May 03, 2024. <https://www.mayoclinic.org/tests-procedures/glucose-tolerance-test/about/pac-20394296>
3. Inzucchi S, Lupsa B. Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults. Updated January 31, 2025. <https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-initial-evaluation-of-diabetes-mellitus-in-adults>
4. Hayward RA, Selvin E. Screening for type 2 diabetes mellitus. Updated December 31, 2024. <https://www.uptodate.com/contents/screening-for-type-2-diabetes-mellitus>
5. Selvin E. Measurements of glycemic control in diabetes mellitus. Updated November 18, 2024. <https://www.uptodate.com/contents/measurements-of-glycemic-control-in-diabetes-mellitus>
6. CDC. CDC National Diabetes Statistics Report. Updated May 15, 2024. <https://www.cdc.gov/diabetes/php/data-research/index.html>
7. ADA. Statistics About Diabetes. Updated November 2, 2023. <https://www.diabetes.org/resources/statistics/statistics-about-diabetes>
8. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. *Diabetes Care*. Jan 1 2023;46(Suppl 1):S19-S40. doi:10.2337/dc23-S002
9. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *The New England journal of medicine*. Feb 09 1984;310(6):341-6. doi:10.1056/nejm198402093100602
10. IEC. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. Jul 2009;32(7):1327-34. doi:10.2337/dc09-9033
11. Kanyal Butola L, Ambad R, Kanyal D, Vagga A. Glycated Haemoglobin-Recent Developments and Review on Non-Glycemic Variables. 2021;doi:10.3390/bios11030070

Reimbursement Policy

12. Hanssen KF, Bangstad HJ, Brinchmann-Hansen O, Dahl-Jorgensen K. Blood glucose control and diabetic microvascular complications: long-term effects of near-normoglycaemia. *Diabetic medicine : a journal of the British Diabetic Association*. Oct 1992;9(8):697-705. doi:10.1111/j.1464-5491.1992.tb01876.x
13. Al-Badri A, Hashmath Z, Oldland GH, et al. Poor Glycemic Control Is Associated With Increased Extracellular Volume Fraction in Diabetes. *Diabetes Care*. Jul 12 2018;doi:10.2337/dc18-0324
14. Gu J, Pan JA, Fan YQ, Zhang HL, Zhang JF, Wang CQ. Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus. *Cardiovascular diabetology*. Jun 30 2018;17(1):96. doi:10.1186/s12933-018-0739-3
15. Tiwari D, Aw TC. The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory. *Exploration of Endocrine and Metabolic Diseases*. 2024;1(4):158-166. doi:10.37349/eemd.2024.00013
16. Durnwald C. Gestational diabetes mellitus: screening, diagnosis, and prevention. Updated March 14, 2025. <https://www.uptodate.com/contents/gestational-diabetes-mellitus-screening-diagnosis-and-prevention>
17. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. *Clinical chemistry*. Jan 2004;50(1):166-74. doi:10.1373/clinchem.2003.024802
18. Weykamp C, John WG, Mosca A, et al. The IFCC Reference Measurement System for HbA1c: a 6-year progress report. *Clinical chemistry*. Feb 2008;54(2):240-8. doi:10.1373/clinchem.2007.097402
19. Gambino R. Glucose: a simple molecule that is not simple to quantify. *Clinical chemistry*. Dec 2007;53(12):2040-1. doi:10.1373/clinchem.2007.094466
20. Petersen PH, Jorgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and hba1c for the diagnosis and prognosis of diabetes mellitus. *Scandinavian journal of clinical and laboratory investigation Supplementum*. 2005;240:51-60. doi:10.1080/00365510500236135
21. Rohlfing C, Wiedmeyer HM, Little R, et al. Biological variation of glycohemoglobin. *Clinical chemistry*. Jul 2002;48(7):1116-8. doi:10.1093/clinchem/48.7.1116
22. Malkani S, Mordes JP. The implications of using Hemoglobin A1C for diagnosing Diabetes Mellitus. *Am J Med*. May 2011;124(5):395-401. doi:10.1016/j.amjmed.2010.11.025
23. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. *Archives of internal medicine*. Jul 23 2007;167(14):1545-51. doi:10.1001/archinte.167.14.1545
24. NGSP. College of American Pathologists (CAP) GH5 Survey Data: . <https://ngsp.org/CAP/CAP23b.pdf>
25. Miller WG, Myers GL, Ashwood ER, et al. State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. *Archives of pathology & laboratory medicine*. May 2008;132(5):838-46. doi:10.5858/2008-132-838-SOTAIT

Reimbursement Policy

26. van 't Riet E, Alsema M, Rijkellohuizen JM, Kostense PJ, Nijpels G, Dekker JM. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. *Diabetes Care*. Jan 2010;33(1):61-6. doi:10.2337/dc09-0677
27. Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. *Diabetes Care*. Nov 1991;14(11):989-93. doi:10.2337/diacare.14.11.989
28. Kramer CK, Araneta MR, Barrett-Connor E. A1C and diabetes diagnosis: The Rancho Bernardo Study. *Diabetes Care*. Jan 2010;33(1):101-3. doi:10.2337/dc09-1366
29. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006. *Diabetes Care*. 2010;33(3):562. doi:10.2337/dc09-1524
30. Mamtara S, Maghsoudlou P, Hasan H, Zhang W, El-Ashry M. Assessing the Clinical Utility of Point of Care HbA1c in the Ophthalmology Outpatient Setting. *Clin Ophthalmol*. 2021;15:41-47. doi:10.2147/OPTH.S287531
31. Goodney PP, Newhall KA, Bekelis K, et al. Consistency of Hemoglobin A1c Testing and Cardiovascular Outcomes in Medicare Patients With Diabetes. *Journal of the American Heart Association*. Aug 10 2016;5(8)doi:10.1161/jaha.116.003566
32. Al Mansari A, Obeid Y, Islam N, et al. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. *BMJ open diabetes research & care*. 2018;6(1):e000519. doi:10.1136/bmjdr-2018-000519
33. Mitsios JP, Ekinici EI, Mitsios GP, Churilov L, Thijs V. Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*. May 17 2018;7(11)doi:10.1161/jaha.117.007858
34. Ludvigsson JF, Neovius M, Söderling J, et al. Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study. *Ann Intern Med*. May 21 2019;170(10):691-701. doi:10.7326/m18-1974
35. Saito Y, Noto H, Takahashi O, Kobayashi D. Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus. *Cancer J*. Jul/Aug 2019;25(4):237-240. doi:10.1097/ppo.0000000000000387
36. Mañé L, Flores-Le Roux JA, Pedro-Botet J, et al. Is fasting plasma glucose in early pregnancy a better predictor of adverse obstetric outcomes than glycated haemoglobin? *Eur J Obstet Gynecol Reprod Biol*. Mar 2019;234:79-84. doi:10.1016/j.ejogrb.2018.12.036
37. Arbiol-Roca A, Pérez-Hernández EA, Aisa-Abdellaoui N, et al. The utility HbA1c test as a screening biomarker for detecting gestational diabetes mellitus. *Clinical Biochemistry*. 2021/04/01/ 2021;90:58-61. doi:10.1016/j.clinbiochem.2021.01.002
38. Tommerdahl KL, Brinton JT, Vigers T, Nadeau KJ, Zeitler PS, Chan CL. Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c. *Pediatr Diabetes*. Dec 2019;20(8):1080-1086. doi:10.1111/pedi.12914

Reimbursement Policy

39. Darukhanavala A, Van Dessel F, Ho J, Hansen M, Kremer T, Alfego D. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis. *PLoS One*. 2021;16(4):e0250036. doi:10.1371/journal.pone.0250036
40. Zhao MJY, Prentice JC, Mohr DC, Conlin PR. Association between hemoglobin A1c variability and hypoglycemia-related hospitalizations in veterans with diabetes mellitus. *BMJ open diabetes research & care*. Jan 2021;9(1)doi:10.1136/bmjdr-2020-001797
41. Merzon E, Green I, Shpigelman M, et al. Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes. *Diabetes Metab Res Rev*. Jul 2021;37(5):e3398. doi:10.1002/dmrr.3398
42. Xie W, Wu N, Wang B, et al. Fasting plasma glucose and glucose fluctuation are associated with COVID-19 prognosis regardless of pre-existing diabetes. *Diabetes Res Clin Pract*. Oct 2021;180:109041. doi:10.1016/j.diabres.2021.109041
43. Yang CY, Li HY, Sung FC, Tan EC, Wei JN, Chuang LM. Relationship between fasting plasma glucose and incidence of diabetes in children and adolescents. *Diabetic medicine : a journal of the British Diabetic Association*. May 2019;36(5):633-643. doi:10.1111/dme.13925
44. Geifman-Holtzman O, Machtinger R, Spiliopoulos M, Schiff E, Koren-Morag N, Dulitzki M. The clinical utility of oral glucose tolerance test at term: can it predict fetal macrosomia? *Arch Gynecol Obstet*. May 2010;281(5):817-21. doi:10.1007/s00404-009-1160-7
45. Bi Y, Yang Y, Yuan X, et al. Association between liver enzymes and type 2 diabetes: a real-world study. Original Research. *Frontiers in Endocrinology*. 2024-February-20 2024;15doi:10.3389/fendo.2024.1340604
46. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S20-S42. doi:10.2337/dc24-S002
47. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. *The Journal of Clinical and Applied Research and Education*. 2025;doi:10.2337/dc25-S002
48. Committee ADAPP. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S111-S125. doi:10.2337/dc24-S006
49. Committee ADAPP. 14. Children and Adolescents: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S258-S281. doi:10.2337/dc24-S014
50. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S282-S294. doi:10.2337/dc24-S015
51. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S179-S218. doi:10.2337/dc24-S010
52. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S52-S76. doi:10.2337/dc24-S004

Reimbursement Policy

53. American Diabetes Association Professional Practice C. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. *Diabetes Care*. Jan 1 2022;45(Suppl 1):S46-S59. doi:10.2337/dc22-S004
54. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S219-S230. doi:10.2337/dc24-S011
55. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S295-S306. doi:10.2337/dc24-S016
56. Diabetes Canada Clinical Practice Guidelines Expert Committee. *Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada*. 2018. <https://www.sciencedirect.com/journal/canadian-journal-of-diabetes/vol/42/suppl/S1>
57. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. *Jama*. Aug 24 2021;326(8):736-743. doi:10.1001/jama.2021.12531
58. USPSTF. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;326(6):531-538. doi:10.1001/jama.2021.11922
59. USPSTF. Grade Definitions. <https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions>
60. Jin J. Screening for Type 2 Diabetes in Children and Adolescents. *JAMA*. Sep 13 2022;328(10):993. doi:10.1001/jama.2022.15240
61. WHO. *Global Report on Diabetes*. 2016. WHO. 2017-02-23 14:02:05. <http://www.who.int/diabetes/global-report/en/>
62. WHO. Diagnosis and Management of Type 2 Diabetes. <https://www.who.int/publications/i/item/who-ucn-ncd-20.1>
63. AAFP. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Recommendation Statement. *American Academy of Family Physicians*. 2022;105(1):Online.
64. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2019;104(5):1520-1574. doi:10.1210/je.2019-00198
65. NICE. Type 2 diabetes in adults: management. NICE. Updated June 29, 2022. <https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations>
66. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan - 2022 Update. *Endocrine Practice*. 2022;28(10):923-1049. doi:10.1016/j.eprac.2022.08.002
67. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm- 2020 Executive Summary. *Endocr Pract*. Jan 2020;26(1):107-139. doi:10.4158/cs-2019-0472

Reimbursement Policy

68. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. *Diabetes Care*. 2023;46(10):e151-e199. doi:10.2337/dci23-0036
69. Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International*. 2022;102(5):S1-S127. doi:10.1016/j.kint.2022.06.008
70. ACG. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Overview. <https://gi.org/topics/steatotic-liver-disease-masld/>

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria.